[Info-Congress. The HOPE Study: Demonstration of the cardiovascular protection of ramipril, an ACE-inhibitor].
The results of the HOPE ("Heart Outcomes Prevention Evaluation") study were presented at the XXIst Congress of the European Society of Cardiology in Barcelona (August 28-September 1, 1999). In addition, results obtained in the large diabetic sub-population (38% of the 9541 patients included in the trial) were reported at the XXXVth Congress of the European Association for the Study of Diabetes in Brussels (September 28-October 2, 1999). The HOPE trial was terminated early because of a reduction of the relative risk (-22%, p < 0.000002) of major cardiovascular events in the group treated with ramipiril compared to the group receiving placebo. Such a favourable effect of ramipril was observed in non-diabetic subjects in secondary prevention and in diabetic patients in secondary or primary prevention. In the latter population, a significant reduction in the incidence of microangiopathic complications (nephropathy and retinopathy) was also demonstrated.
Scheen
A J
AJ
Service de Diabétologie, Nutrition et Maladies métaboliques, Université de Liège.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications; D006801:Humans; D017257:Ramipril / Q000627:therapeutic use*; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D017257:Ramipril